Master
TITILE OF THE PROJECT
pH SENSITIVE CHITOSAN DERIVATIVE POLYMERICS NANOPARTICLES AS DRUG CARRIER IN TARGETING COLON CANCER CELLS
INTRODUCTION:
Cancers area group of diseases characterized by uncontrolled growth of abnormal cells in tissues and its leading cause of death. To date, cancer caused 7.6 million deaths (around 13% of all deaths) around the world and this will projected to continue to rise to over 13.1 million deaths in 2030. Among this colon cancer arises when this uncontrolled cell growth initiated within cells in the large intestine. Most colon cancers originate from small, noncancerous (benign) tumors called adenomatous polyps that form on the inner walls of the large intestine. Some of these polyps may grow into malignant colon cancers over time and these cancerous cells may travel through the blood and lymph systems, spreading to other parts of the body. These cancer cells can grow in several places, invading and destroying other healthy tissues throughout the body. This process itself is called metastasis, and the result is a more serious condition that is very difficult to treat. The most common treatment for such cancer is frequent radiation and chemotherapy which has serious side effects, resulting in poor patient compliance. Recently, there has been a growing interest in developing new carrier or delivery system which would be able to protect the normal cells and kill the cancer cells. In general chemotherapeutic agents has some limitations such as poor solubility; insufficient physical stability (shelf-life); low bioavailability; short in vivo stability (half-life); strong side-effects; regulatory issue/hurdles; and lack of large scale production. To overcome these problems, therapeutic agent needs to be combined with a smart drug delivery system and/ or delivery technology to make it applicable for the treatment of colon cancer. The ultimate goal of drug delivery research is to help patients by developing clinically useful
pH SENSITIVE CHITOSAN DERIVATIVE POLYMERICS NANOPARTICLES AS DRUG CARRIER IN TARGETING COLON CANCER CELLS
INTRODUCTION:
Cancers area group of diseases characterized by uncontrolled growth of abnormal cells in tissues and its leading cause of death. To date, cancer caused 7.6 million deaths (around 13% of all deaths) around the world and this will projected to continue to rise to over 13.1 million deaths in 2030. Among this colon cancer arises when this uncontrolled cell growth initiated within cells in the large intestine. Most colon cancers originate from small, noncancerous (benign) tumors called adenomatous polyps that form on the inner walls of the large intestine. Some of these polyps may grow into malignant colon cancers over time and these cancerous cells may travel through the blood and lymph systems, spreading to other parts of the body. These cancer cells can grow in several places, invading and destroying other healthy tissues throughout the body. This process itself is called metastasis, and the result is a more serious condition that is very difficult to treat. The most common treatment for such cancer is frequent radiation and chemotherapy which has serious side effects, resulting in poor patient compliance. Recently, there has been a growing interest in developing new carrier or delivery system which would be able to protect the normal cells and kill the cancer cells. In general chemotherapeutic agents has some limitations such as poor solubility; insufficient physical stability (shelf-life); low bioavailability; short in vivo stability (half-life); strong side-effects; regulatory issue/hurdles; and lack of large scale production. To overcome these problems, therapeutic agent needs to be combined with a smart drug delivery system and/ or delivery technology to make it applicable for the treatment of colon cancer. The ultimate goal of drug delivery research is to help patients by developing clinically useful
References: 1) Shahrooz Saremi, Fatemeh Atyabi, Seyedeh Parinaz Akhlaghi, Seyed Nasser Ostad, Rassoul Dinarvand. Thiolated chitosan nanoparticles for enhancing oral absorption of docetaxel:preparation,in vitro and ex vivo evaluation. International Journal of Nanomedicine 2011:6 119–128. 2) Hosniyeh Hosseinzadeh, Fatemeh Atyabi, Rassoul Dinarvand, Seyed Naser Ostad. Chitosan–Pluronic nanoparticles as oral delivery of anticancer gemcitabine: preparation and in vitro study. International Journal of Nanomedicine 2012:7 1851–1863. 3) Carla Mura, Maria Manconi, Donatella Valenti, Maria Letizia Manca, Octavio Díez-Sales, Giuseppe Loy, Anna Maria Fadda. In vitro study of N-succinyl chitosan for targeted delivery of 5-aminosalicylic acid to colon. Carbohydrate Polymers, Volume 85, Issue 3, 1 June 2011, Pages 578-583. 4) Aiedeh, K., and Taha, M. O. 1999. Synthesis of chitosan succinate and chitosan phthalate and their evaluation as suggested matrices in orally administered,colon specific drug delivery systems. Arch. Pharm. Pharm. Med. Chem.332:103. 5) Subramanya K. Bhat, J. Keshavayya, Venkatrao H. Kulkarni, Venugoapala K. R. Reddy, Preeti V. Kulkarni, Anandrao R. Kulkarni. Preparation and characterization of crosslinked chitosan microspheres for the colonic delivery of 5-fluorouracil. Journal of Applied Polymer Science. Volume 125, Issue 3, pages 1736–1744, 5 August 2012 6) C. Mura, A. Nácher, V. Merino, M. Merino-Sanjuan, C. Carda, A. Ruiz, M. Manconi, G. Loy, A.M. Fadda, O. Diez-Sales. N-Succinyl-chitosan systems for 5-aminosalicylic acid colon delivery: In vivo study with TNBS-induced colitis model in rats. International Journal of Pharmaceutics. Volume 416, Issue 1, 15 September 2011, Pages 145–154